UnknownPhase 4

Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

South Korea40 participantsStarted 2020-09-03

Plain-language summary

The clinical study determines the effect of Evogliptin in patients with type 2 diabetes mellitus and chronic hepatitis B to confirm the improvement of hepatic fibrosis.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients who are newly diagnosed as type 2 diabetes : 6.5% ≤ HbA1c \< 10.0%
✓. Patients who are already diagnosed as type 2 diabetes: HbA1c \< 10.0%

What they're measuring

Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)

Timeframe: Baseline

Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)

Timeframe: Baseline to 24 weeks (±7days)

Trial details

NCT IDNCT04584242

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05

Contact for this trial

Seung Up Kim

+82-2228-1982 ksukorea@yuhs.ac

View on ClinicalTrials.gov More Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes trials